Glenmark’s Ryaltris ‘Ahead Of The Game’ In Markets, COVID-19 Nasal Spray Coming
Executive Summary
There is momentum for Glenmark’s Ryaltris across new launch markets internationally, with FY2023 and FY2024 seen as important years for revenue scale-up. A partnered nitric oxide nasal spray for COVID-19 faces trial recruitment challenges in India but the firm hopes to be able to debut the product this year.
You may also be interested in...
Lotus To Commercialize Glenmark’s Ryaltris Nasal Spray In SE Asia
Glenmark is set to roll out its allergic rhinitis nasal spray Ryaltris in three South East Asian countries following an exclusive licensing agreement with Lotus. The company expects Ryaltris to have a significant role to play in its growth over the coming years.
Hikma Set For Ryaltris Take Off As Glenmark Wins USFDA Nod
Glenmark is celebrating a “major milestone,” after its Ryaltris nasal spray to treat seasonal allergic rhinitis was approved by the FDA. Hikma will handle commercialization in the US, as part of its continued specialty push in the market.
Ichnos Gets Going With Almirall Deal, Multiple Myeloma Bispecifics Add Sheen
Glenmark’s US-based innovation arm Ichnos delivers first licensing deal for IL-1RAP antagonist, while early data for a bispecific antibody demonstates promising activity in multiple in vitro and in vivo tumor models relative to daratumumab and magrolimab.